Comparative Pharmacology
Head-to-head clinical analysis: FEMSTAT versus NYSERT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FEMSTAT versus NYSERT.
FEMSTAT vs NYSERT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
FEMSTAT (butoconazole) is an imidazole antifungal agent that inhibits fungal cytochrome P450 14α-demethylase, thereby blocking the conversion of lanosterol to ergosterol, a key component of the fungal cell membrane. This disrupts membrane integrity and function, leading to fungal cell death.
NYSERT is a fixed-dose combination of nystatin and sertaconazole. Nystatin, a polyene antifungal, binds to ergosterol in fungal cell membranes, disrupting permeability and causing cell death. Sertaconazole, an azole antifungal, inhibits lanosterol 14α-demethylase (CYP51), blocking ergosterol synthesis and accumulation of toxic methylsterols. Synergistic action provides broad-spectrum antifungal activity against Candida spp. and dermatophytes.
Butoconazole nitrate 2% vaginal cream: one applicatorful (approximately 5 g) intravaginally at bedtime for 3 days. Alternatively, butoconazole nitrate 2% single-dose vaginal cream: one applicatorful (approximately 5 g) intravaginally as a single dose.
10 mg orally once daily at bedtime, with or without food.
None Documented
None Documented
Terminal half-life: 6-9 hours; clinical context: supports twice-daily dosing for consistent therapeutic levels.
Terminal elimination half-life approximately 20-25 hours in healthy adults; prolonged in hepatic impairment (up to 40 hours) and in elderly patients.
Primarily hepatic metabolism; <10% excreted unchanged in urine. Fecal excretion accounts for approximately 30% of metabolites.
Primarily hepatic metabolism (CYP3A4) followed by biliary excretion of metabolites; ~60% fecal, ~30% renal (as metabolites), <5% unchanged in urine.
Category C
Category C
Antifungal
Antifungal